Liver Diseases Therapeutics Market Snapshot
|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The liver diseases therapeutics market is expected to register a CAGR of nearly 11.01% during the forecast period, with a revenue of approximately USD 19,745 million in 2020. It is expected to reach USD 36,812 million by 2026. The market will show rapid growth due to the increasing incidence of liver diseases, increased consumption of alcohol and improper diet, and rising government initiatives of providing vaccines and growing awareness.
The rising number of COVID-19 cases has found liver disease involvement. The cause of liver injury in COVID‐19 can be attributed to multiple factors, including virus‐induced systemic inflammation, hypoxia, hepatic congestion, and drug-induced liver disease. Among patients with cirrhosis, COVID‐19 has been associated with hepatic decompensation and liver‐related mortality. COVID‐19’s impact on healthcare resources has adversely affected the delivery of care and outcomes of patients with chronic liver disease. Therefore, there has been a decrease in the treatment, diagnosis, and follow-up of patients with liver disease, which had negative consequences in the overall healthcare industry. Also, the clinical trials of drugs have slowed down as most companies have delayed the start for most of the new studies in several countries.
Chronic liver diseases (CLDs) are major public health problems globally. The liver is, in many ways, the reflection of a person’s health and should play a central role in public health policies across the world. The mortality rate due to chronic liver disease continues to rise, driven largely by a spike in nonalcoholic fatty liver disease (NAFLD), according to results from an analysis of national data.
According to a study “Burden of Liver Diseases in the World,” published in 2019, liver disease accounted for approximately 2 million deaths per year worldwide, out of which 1 million are due to complications of cirrhosis and 1 million are due to viral hepatitis and hepatocellular carcinoma. Thus, cirrhosis is the 11th most common cause of death worldwide, and liver cancer is the 16th leading cause of death. Combined, they account for 3.5% of all deaths across the world. Also, chronic liver disease mortality is expected to rise in the United States, driven largely by a spike in nonalcoholic fatty liver disease (NAFLD). The rising incidence of liver diseases helped in driving the market’s growth. Therefore increasing liver diseases has helped in driving the overall market.
In the United Kingdom, the primary causes of liver diseases include alcohol, obesity, and viral hepatitis. Furthermore, about 1,000 liver transplants are performed each year, and due to insufficient liver donors, people are dependent on the therapeutics available in the market. All the aforementioned factors are expected to drive the market’s growth.
Furthermore, with the increasing prevalence of liver diseases, government and other not-for-profit organizations play a crucial role in the rising awareness about liver diseases across the globe. Hence all these organizations are found promoting the awareness of liver-related diseases and support for research and development for the prevention, treatment, and cure of liver diseases.
Scope of the Report
As per the scope of the report, liver disease is either inherited or is caused by factors that damage the liver, such as viruses and the usage of alcohol. The liver disease, if not treated, damages the liver that further leads to liver failure. Therefore some of the major drugs used in treating various types of liver diseases include vaccines, immunosuppressants, chemotherapy drugs, and anti-viral drugs. The liver diseases therapeutics market is segmented by treatment type (anti-viral drugs, targeted therapy, immunosuppressant drugs, chemotherapy drugs, immunoglobulin, vaccines, and other treatment types), end user (hospitals, ambulatory surgery centers, and other end users), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.
|By Treatment Type|
|Anti Viral Drugs|
|Other Treatment Types|
|By End User|
|Ambulatory Surgery Centers|
|Other End Users|
Key Market Trends
The Anti Viral Drugs Segment is Expected to Dominate the Market During the Forecast Period
With the rising prevalence of liver diseases and the increasing consumption of alcohol, the demand for liver diseases therapeutics is increased significantly.
Due to the COVID-19 pandemic, it has been found that currently, there is no antiviral drug that is directed against SARS-CoV-2, and many patients with COVID-19 are administered antivirals authorized for other therapeutic indications. A recent study published in 2021 has shown that although arbidol treatment does not seem to be significantly associated with liver injury complications, the overall use of antiviral drugs increases the risk of liver injury for critically ill patients with COVID-19. Antiviral drugs are widely used to treat COVID-19 but are not recommended for critically ill patients. However, the effect of antiviral treatment on liver injury in critically ill patients is not yet clear.
Antiviral drugs are a class of medication used for HBV (hepatitis B virus) that are effective in suppressing the HBV viral load while reducing the risk of developing cirrhosis and hepatocellular carcinoma. Some of the FDA-approved drugs include Mavyret, Zepatier, and Vosevi. These drugs have been widely used for many years. They are safe and effective, especially for patients with signs and symptoms of moderate-to-severe liver impairment or other serious liver problems.
Therefore, the antiviral drug segment holds a major market share, and it is expected to maintain its lead position during the forecast period. This is attributed to the high incidence of virus-infected liver diseases, including Hepatitis. Thus, antiviral drugs are often taken to suppress the hepatitis B virus and long-term complications associated with hepatitis B, including liver disease and impairment. Thus, there is a need for liver transplantation and hepatocellular carcinoma.
Also, various drug approvals, along with the commercialization of several anticipated pipeline drugs, are expected to drive the growth of the market studied.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Liver Disease Therapeutics Market
North America dominates the market due to research and academic institutes conducting clinical trial studies in the region. Changing lifestyles such as increasing consumption of alcohol and unhealthy diets have also increased the incidences of liver disease. Moreover, growing patient awareness levels and the introduction of new products targeting unmet medical needs are expected to drive regional market growth over the forecast period.
Since the COVID-19 outbreak, the market has been negatively impacted due to the supply chain and market disruption and its financial impact on firms and financial markets. The pandemic has negatively impacted the pharmaceutical industry in terms of the supply and demand for different drugs. Similarly, it is also expected to impact the overall growth of the global liver disease therapeutics market.
There has been an increase in the number of deaths due to liver diseases and the rising incidence of liver cancer. According to the Centers for Disease Control and Prevention, in the United States, between 800,000 and 1.4 million people are suffering from chronic hepatitis B infection. Currently, in the United States, there are about 43,000 hepatitis B cases each year. Furthermore, about 15-25% of the people suffering from chronic hepatitis B are expected to develop serious liver diseases, such as cancer, cirrhosis (scarring of the liver), or liver failure, all of which can be fatal.
According to the Canadian Liver Foundation, non-alcoholic fatty liver disease (NAFLD) affects about 20% of Canadians in Canada. The most common cause of fatty liver disease in Canada is obesity. In 2018, almost 30% of Canadians 18 and older (roughly 7.3 million adults) reported height and weight classified as either overweight or obese. This helps in increasing liver diseases, thereby boosting the overall market demand.
Based on an article published by Mayo Clinic 2019, therapies were available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis. Drug therapy thus may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers.
Therefore, due to the rising prevalence of liver diseases, the management of liver diseases evolved rapidly. Several therapeutic options are available in the market, primarily related to preventing liver disease progression and anticipated liver morbidity and mortality. Moreover, growing patient awareness levels and the introduction of new products targeting unmet medical needs are expected to drive regional market growth over the forecast period.
To understand geography trends, Download Sample Report
Various companies are found investing in their R&D to develop innovative and advanced treatment drugs for liver diseases. Therefore, research and development of highly efficient and less or no side effects pharmaceutical drugs would drive the market in the near future. The companies are also found focusing on organic growth strategies such as product launches, product approvals, and others such as patents and events.
- In May 2020, Enanta Pharmaceuticals Inc. announced topline results from its INTREPID Phase 2 study of EDP-305, a Farnesoid X receptor (FXR), in subjects with primary biliary cholangitis.
- In April 2020, Alnylam Pharmaceuticals Inc. collaborated with Dicerna Pharmaceuticals Inc. for the development and commercialization of investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.
Table of Contents
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Incidence of Liver Diseases
4.2.2 Increase in the Consumption of Alcohol and Improper Diet
4.2.3 Rising Government Initiatives to Provide Vaccines and Growing Awareness
4.3 Market Restraints
4.3.1 Side Effects and Risks Associated with Drugs
4.3.2 Stringent FDA Approvals and Other Government Regulations
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Anti Viral Drugs
5.1.2 Targeted Therapy
5.1.3 Immunosuppressant Drugs
5.1.4 Chemotherapy Drugs
5.1.7 Other Treatment Types
5.2 By End User
5.2.2 Ambulatory Surgery Centers
5.2.3 Other End Users
5.3.1 North America
18.104.22.168 United States (By Treatment Type and End User)
22.214.171.124 Canada (By Treatment Type and End User)
126.96.36.199 Mexico (By Treatment Type and End User)
188.8.131.52 Germany (By Treatment Type and End User)
184.108.40.206 United Kingdom (By Treatment Type and End User)
220.127.116.11 France (By Treatment Type and End User)
18.104.22.168 Italy (By Treatment Type and End User)
22.214.171.124 Spain (By Treatment Type and End User)
126.96.36.199 Rest of Europe (By Treatment Type and End User)
188.8.131.52 China (By Treatment Type and End User)
184.108.40.206 Japan (By Treatment Type and End User)
220.127.116.11 India (By Treatment Type and End User)
18.104.22.168 Australia (By Treatment Type and End User)
22.214.171.124 South Korea (By Treatment Type and End User)
126.96.36.199 Rest of Asia-Pacific (By Treatment Type and End User)
5.3.4 Middle-East and Africa
188.8.131.52 GCC (By Treatment Type and End User)
184.108.40.206 South Africa (By Treatment Type and End User)
220.127.116.11 Rest of Middle-East and Africa (By Treatment Type and End User)
5.3.5 South America
18.104.22.168 Brazil (By Treatment Type and End User)
22.214.171.124 Argentina (By Treatment Type and End User)
126.96.36.199 Rest of South America (By Treatment Type and End User)
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Astellas Pharma Inc.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Gilead Sciences
6.1.5 GlaxoSmithKline PLC
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Merck & Co. Inc.
6.1.8 Novartis AG
6.1.9 Sanofi AG
6.1.10 AbbVie Inc.
6.1.11 Endo International PLC
6.1.12 Pfizer Inc.
6.1.13 Takeda Pharmaceutical
6.1.14 Alnylam Pharmaceuticals Inc.
6.1.15 Provectus Biopharmaceuticals Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Liver Diseases Therapeutics Market market is studied from 2018 - 2026.
What is the growth rate of Liver Diseases Therapeutics Market?
The Liver Diseases Therapeutics Market is growing at a CAGR of 11.01% over the next 5 years.
What is Liver Diseases Therapeutics Market size in 2018?
The Liver Diseases Therapeutics Market is valued at 19745 Million USD in 2018.
What is Liver Diseases Therapeutics Market size in 2026?
The Liver Diseases Therapeutics Market is valued at 36812 Million USD in 2026.
Which region has highest growth rate in Liver Diseases Therapeutics Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Liver Diseases Therapeutics Market?
North America holds highest share in 2020.
Who are the key players in Liver Diseases Therapeutics Market?
Abbott Laboratories, Gilead Sciences, Novartis AG, Sanofi, Astellas Pharma Inc. are the major companies operating in Liver Diseases Therapeutics Market.